NADPH oxidase isoform-specific inhibitors have been developed recently, specifically NOX1 inhibitors, such as ML171 and NoxA1ds, that block the interaction of NoxA1 with NOX1, reducing vascular resistance, improving endothelial function, and decreasing fat differentiation and migratory potential in MetS (Sela et al., 2015; Camargo et al., 2018). Here, NOX1 is linked to metabolic syndrome.